| BSE: 532523 | Sector: Health care |
| NSE: BIOCON | ISIN Code: INE376G01013 |
| BSE 00:00 | 20 Feb | 315.00 |
8.95 (2.92%) |
OPEN
305.80 |
HIGH
319.05 |
LOW
305.00 |
| NSE 00:00 | 20 Feb | 315.05 |
8.95 (2.92%) |
OPEN
305.95 |
HIGH
319.00 |
LOW
305.80 |
| OPEN | 305.80 |
| PREVIOUS CLOSE | 306.05 |
| VOLUME | 230972 |
| 52-Week high | 320.75 |
| 52-Week low | 211.30 |
| P/E | 124.51 |
| Mkt Cap.(Rs cr) | 37,800 |
| Buy Price | 315.00 |
| Buy Qty | 19.00 |
| Sell Price | 316.00 |
| Sell Qty | 453.00 |
Biocon Limited is India's largest and fully-integrated innovation-led biopharmaceutical company. Some of its key brands are INSUGEN (rh-insulin) BASALOG (Glargine) CANMAb (Trastuzumab) BIOMAb-EGFR (Nimotuzumab) KRABEVAA (Bevacizumab) and ALZUMAb (Itolizumab) a 'first in class' anti-CD6 monoclonal antibody. The company has a rich pipeline of Biosimilars and Novel Biologics at various stages of deve...> More
| COMPANY INFORMATION | |||||||
| Chairperson & Managing Direct : | Kiran Mazumdar Shaw | ||||||
| Vice Chairman : | John Shaw | ||||||
| Director : | Ravi Mazumdar | ||||||
| Independent Director : | Russell Walls | ||||||
| Independent Director : | Mary Harney | ||||||
| Independent Director : | Daniel M Bradbury | ||||||
| Independent Director : | Jeremy Levin | ||||||
| Independent Director : | Vijay Kumar Kuchroo | ||||||
| Independent Director : | M Damodaran | ||||||
| Independent Director : | Bobby Kanubhai Parikh | ||||||
| Company Secretary : | Mayank Verma | ||||||
| Joint Managing Director & CEO : | SIDDHARTH MITTAL | ||||||
| AUDITOR : | B S R & Co LLP | ||||||
| IND NAME : | Pharmaceuticals - Indian - Bulk Drugs & Formln | ||||||
| HOUSE NAME : | Indian Private | ||||||
| Registered office | |||||||
| 20th KM Hosur Road Hebbagodi, Electronic City P O,Bangalore,Karnataka-560100 | |||||||
| Ph : 91-80-28082808 | |||||||
| WEBSITE : http://www.biocon.com | |||||||
| E-mail : co.secretary@biocon.com | |||||||
